British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.

Slides:

Advertisements

Similar presentations

Diagnosing Tuberculosis Pamela Hepple Medecins Sans Frontieres UK.

Advertisements

ISTC Training Modules 2008 Your name Institution/organization Meeting Date.

Molecular testing for detection of Mycobacterium tuberculosis San Francisco Department of Public Health Laboratory.

Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.

Agenda Background Current testings Xpert MTB/RIF product PAGE | 1.

Ruqaya Mustafa Ali Genetic Engineering and Biotechnology.

Improving diagnosis TB laboratory strengthening.

1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.

DR.RAGHAVENDRA.H.GOBBUR

Standards for Laboratory Diagnosis of Tuberculosis Professor Brian I. Duerden Inspector of Microbiology and Infection Control, Department of Health.

Access to TB Drugs and Diagnostics Gregg Gonsalves Open Society Foundations Division of the Epidemiology of Microbial Diseases, Yale School of Public Health.

Module 11: Clinical guide to Xpert MTB/RIF Global Laboratory Initiative – Xpert MTB/RIF Training Package.

Dr. Raz Mohammed WALI Chief Migration Health Physician NTP National Seminar: July 2014 Pukhra, Nepal.

What Gold Standard for Rifampicin Testing?: the future of molecular testing TAG Meeting, Manila, 9-12 December 2014 Richard Lumb Mycobacterium Reference.

Second Line Drugs Susceptibility Testing: Study Progress Report Alex Sloutsky Massachusetts State TB Laboratory Paris, 2005.

TB Diagnostics: Update on Policies and Pipeline

ISDH Lab TB Testing Update Lixia Liu PhD MP(ASCP) September 16, 2010.

COMPREHENSIVE APPROACH TO TB DIAGNOSIS

Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.

Module 1: Overview of tuberculosis (TB) and TB diagnostics Global Laboratory Initiative – Xpert MTB/RIF Training Package.

Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,

Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director

Vall d’Hebron Servei de Microbiologia External quality assurance for drug susceptibility testing of M. tuberculosis against second line anti-tuberculosis.

Part 2 Performing drug susceptibility testing on solid media Module 10 1.

LABORATORIES and DIAGNOSIS of TUBERCULOSIS Assoc. Prof. Alpaslan Alp Hacettepe University Faculty of Medicine Department of Medical Microbiology.

Tuberculosis Research of INA-RESPOND on Drug-resistant

Introduction to the course 1. Agenda Include: TECHNICAL ISSUES PRACTICAL ISSUES 2.

Diagnosis of TB: what is new from the laboratory

CLINICAL DIAGNOSTIC TB LABORATORY Alexander Sloutsky, Director University of Massachusetts Supranational Reference TB Laboratory Boston, MA.

Experience with Tb diagnostics and Scale up of services Botswana, Nigeria, and Tanzania Ernest Ekong, MD,MPH National Clinical Coordinator Harvard PEPFAR.

Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.

Implementation of Thin Layer Agar for Mycobacterium culture in rural Kenya Médecins Sans Frontières.

PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.

Revision of new diagnostics for TB

TB Methodologies Dr. John G. Magee Regional Reference Centre for Mycobacteriology Health Protection Agency Regional Laboratory, Newcastle upon Tyne.

Barbara Laughon NIAID, NIH Report of TB/HIV Diagnostics Task Force.

Molecular diagnosis of drug resistant tuberculosis by a DNA array

Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.

TB notification.

Patient with Presumptive TB HIV Status PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB.

By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.

Diagnostic algorithms of TB case finding and their effect on TB epidemiology in Russian Regions Andrey Maryandyshev, Elena Nikishova Northern State Medical.

LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.

Laboratory Diagnosis of Tuberculosis By Dr. Faten Aly Shoukry, Ph D Consultant & Head of Microbiology Department, Abbassia Chest Hospital.

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

Measures to Decrease TB Prevalence in the Barents Region Andrey O. Maryandyshev Elena I. Nikishova Dmitry V. Perkhin.

REMoxTB – a microbiological challenge Dr Anna Bateson Dr. Tim McHugh, Robert Hunt, Emma Cunningham (Emily Bongard, Holly Ciesielczuk)

TB – LABORATORY INVESTIGATIONS by Dr. Zubaidah Abdul Wahab Datin Dr. Ganeswrie Raj 1.

Drug Resistant Tuberculosis

CASES OF PLEURAL EFFUSION (n=56)

Control of tuberculosis in Serbia:

TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.

Summary of changes in the RNTCP technical guidelines in

Centre for Clinical Microbiology Meeting

Drug Resistant (DR) TB (Back to Basics)

Part 1 Principles of resistance to antituberculosis drugs

Laboratory Testing for Tuberculosis

Laboratory ‘Network’ Update New York State Department of Health

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm S.O. Simons, T. van der Laan,

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.

Module 9 Recording and reporting culture results

Timeline of development of key elements of the Cambodian MDR-TB treatment programme. *GLC1 application for patients enrolled in the CAMbodian Early vs.

Deciphering TB Lab Reports

T. Schön, P. Miotto, C.U. Köser, M. Viveiros, E. Böttger, E. Cambau

DIAGNOSIS OF TUBERCULOSIS

Treatment of Drug Resistant TB - Questions

Diversity of resistant and susceptible isolates.

Synchronization of a basic diagnostic algorithm (linked diagnostic tests) with different levels of diagnostic services. Synchronization of a basic diagnostic.

Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,

Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.

Presentation transcript:

British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London With assistance from FINDdiagnostics

Diagnostic testing at different levels of health system Peripheral health centre Proportion of patients TB tests Peripheral centre60%None Microscopy centre35%Microscopy Referral laboratory10%Culture, DST Reference laboratory5%Reference methods

Sputum: 25 years ago (1985) 1.Poor countries: Microscopy alone 2.Richer countries. Microscopy, LJ culture, DST 3.Advanced countries. Microscopy, Liquid culture, ID, DST

Direct smears Culture on LJ slopes (3-6 weeks) Identification as M. tuberculosis (Chemical; PNB, niacin, catalase) Drug susceptibility tests (DSTs) (Rifampicin screen) Sputum bacteriology UK (1985)

FIND and Carl Zeiss Micro Imaging GmbH have co- developed a fluorescent LED microscope based on the proven Primo Star platform. FIND/Zeiss microscope offers superior optics, reflected light illumination, easy switch from brightfield to fluorescent light

Direct smears Fluorescence v. Bright field microscopy Fluorescence: Introduced in 1940s. 5x more rapid than Bright field BUT: Mercury vapour bulb: Expensive. Limited life. Gradual decline. LED illumination introduced during past 5 years Find/Zeus collaboration

Culture: solid v. liquid Solid: LJ slopes. 7H11 slopes or plates. Liquid: Early attempts high contamination Selective medium paper (Mitchison et al J Med Microbiol 1971; 5: 165) Penta used in Bactec machine Automated liquid systems v. solid media Sensitive. Rapid. Contamination. NTMs v. TB.

Genetic systems Equipment cost Cost specimen (£) Sm + Cult + Sm – Cult + Specifity Hain TBDR+Moderate4898%100% Gene Xpert (Cepherd) High (£100,000) 4099%87%97% LAMP (Eiken) Low 98%49%99% Sensitivity

Culture, identification & DSTs HAIN MDTBDR plus PCR & Line probe based 1. Identifies as TB complex. 2.DSTs for RIF & INH (95%) Can be used directly on sputum avoiding culture

What to do about MDR TB? (MDR = Resistance to INH & RIF) Genetic tests for reserve drugs not adequate yet. Therefore cultures in liquid or on solid medium necessary as well as genetic techniques.

Reserve drugs FluoroquinolonesEthionamide MoxifloxacinProthionamide LevofloxacinCycloserine InjectablesPAS StreptomycinLinezolid Amikacin (Kanna)Amoxicillin/clavulanate Capreomycin Ethambutol Pyrazinamide

MGIT 960 Reserve Critical Concentrations 1 Rusch-Gerdes S et al. JCM 2006;44: Rodrigues C et al. IJTLD; 2008;12: Kruuner A et al. JCM 2006;44: Drug Study 1 Study 2Study 3 Amikacin1.0 KanamycinND2.5ND Capreomycin Ethionamide5.0 ND Proteonamide2.5ND2.5, 5.0 Ofloxacin MoxifloxacinND LevofloxacinND Rifabutin0.5ND0.5 PASND4.0ND Linezolid1.0ND

DSTs Phenotypic Classic on LJ slopes or 7H11 plates. Takes 7 weeks +. MGIT or other automated liquid tests. Microcolony methods Liquid medium: Mods. Sensitive, time consuming, ?dangerous Solid medium: Thin layer agar (TLA): Quicker. Less dangerous

Phenotype DST Thin-layer agar plate (TLA) method 7H11 thin layer plates made selective Each plate with up to 6 strains in quadrants Control: no drug PNB (p-nitrobenzoate): TB inhibited. INH 0.2 µg/ml RIF 2.0 µg/ml SM 2.0 µg/ml PZA 2,000 µg/ml nicotinamide etc

What is drug resistance? Defined from distribution of MICs on ‘wild’ strains

Studies of early bactericidal activity define the ‘therapeutic’ margin

Can high drug dosage still have an effect on resistant strains? IsoniazidMutants katG – high MIC inhA – low MIC Early clinical trial Guinea-pig study QuinolonesMutantsMainly in gyrA – low MIC